June 1, 2014
Zestagen alerts cancer patients that its antibody is NOT approved for clinical usage of any kind in any country and is NOT available for human use. It appears that certain individuals promise treatment with our antibodies in Russia, Turkey and other countries. These are all spurious and potentially fraudulent activities that we strongly disapprove of. Any potential damage, loss or tort arising from these spurious activities or representations is expressly disclaimed by Zestagen S.A.
April 5, 2013
Zestagen announces that it was selected to present at the Chicago Bio International Conference, April 22-25 2013. Of the 2,700 companies participating at the 2013 BIO convention, approximately 130 were invited to present. As of April 12, only 5 companies were registered as monoclonal antibody companies presenting at BIO -3 out of the 5 are biosimilar Ab companies- while the rest 2 are comprised of Zestagen and another biotech company. For more details of this years’ presenters please visit this link.
March 23, 2013
Zestagen announces it has been selected to present at the BioTrinity 2013 Investor Conference on May 15, 2013 (Newbury, UK).
March 16, 2013
Zestagen announces it has received a Top Innovator Award and an invitation to present at the Life Sciences Healthcare & Venture Summit (New York City, March 20, 2013).
March 7, 2013
Zestagen announces that Bruce R. Zetter, PhD, Charles Nowiszewski Professor in the Departments of Cell Biology and Surgery at Harvard Medical School, has joined Zestagen's Scientific Advisory Board.
February 20, 2013
A Board of Swiss investors selects Zestagen SA as #1 biotech company to invest in on behalf of the prestigious Swiss economic review BILAN. For a full version of the article, follow this link (in French).
The following publications are highly relevant to Zestagen's monoclonal antibodies against ehsp90.
1. El Hamidieh et al.,
PLoS One. 2012;7(8):e42722.
2. Sidera et al., PLoS One. 2011;6(9):e23906.
3. Stellas et al., BMC Cell Biol. 2010 Jul 5;11:51.
4. Sidera et al., J Biol Chem. 2008 Jan 25;283(4):2031-41.
5. Sidera and Patsavoudi, Cell Cycle. 2008 Jun 1;7(11):1564-8.
6. Stellas et al., Clin Cancer Res. 2007 Mar 15;13(6):1831-8.
7. Sidera et al., J Biol Chem. 2004 Oct 29;279(44):45379-88.
8. Yfanti et al., Glia. 2004 Jan 1;45(1):39-53.
9. Yfanti et al., J Neurochem. 1998 Oct;71(4):1381-9.
10. Thomaidou et al., J Neurochem. 1995 May;64(5):1937-44.
Zestagen's Corporate Materials can be downloaded as follows (password protected).
Quoted from Li et al, 2013, Los Angeles University:
“pharmaceutical agents that selectively target eHsp90 should be more effective on tumor cells and less toxic on normal cells than current inhibitors that nondiscriminatively target both extracellular and intracellular Hsp90.”